Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 100%

Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection

Palivizumab showed no clear difference in number of children reporting any SAE compared with motavizumab (high certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 1.04 [0.96, 1.13]
4 studies · 8238 participants
High

Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection

Palivizumab leads to lower number of children reporting any SAE compared with placebo (high certainty).

1 finding from 1 review